City
Epaper

Study shows tumour DNA in blood can predict lung cancer outcome

By IANS | Updated: January 13, 2025 16:35 IST

New Delhi, Jan 13 A team of British scientists has found that a blood test used to detect ...

Open in App

New Delhi, Jan 13 A team of British scientists has found that a blood test used to detect circulating tumour DNA can predict the outcome of lung cancer.

Circulating tumour DNA (ctDNA) is fragments of DNA released into the blood by tumours. It’s known to be important for disease prognosis but can be difficult to measure precisely.

In the study, scientists from the Francis Crick Institute and University College London used a whole-genome sequencing platform called NeXT Personal, which can detect very small amounts -- 1 part per million -- of ctDNA.

They used the platform to test blood plasma samples from 171 people with early-stage lung cancer.

The finding published on Monday in the journal Nature Medicine showed that people with a low level of ctDNA before surgery were less likely to relapse and had improved overall survival rates than people with a high level of ctDNA.

The high sensitivity of the test meant that smaller amounts of ctDNA could be detected, which prevented people with a lower amount of ctDNA from being incorrectly labelled ctDNA negative.

“We’ve shown that the presence or absence of tumour DNA in the blood was strongly predictive of prognosis. ctDNA testing, especially using ultrasensitive platforms, could help clinicians make more informed decisions about treatment and give patients a more accurate idea of how their disease might progress,” said James Black, Postdoctoral Clinical Fellow at the Francis Crick Institute.

Current treatment for early-stage lung cancer includes removing the tumour by surgery and with chemotherapy or immunotherapy. The treatment course depends on the stage of the tumour, which aims to achieve the highest chance of cure.

Meanwhile, the team noted that the test will next be assessed on samples from patients who have undergone surgery with the earliest stages of lung cancer. This will help evaluate if the presence of ctDNA post-operatively in blood can be used to infer future risk of relapse.

This could allow doctors to offer additional therapy after surgery, increasing the chance of curing patients, the scientists said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other SportsBayern veteran Thomas Muller announces second season with the Whitecaps in MLS

LifestyleChampa Shashthi 2025: What You Can Eat During the Khandoba Navratri Fast

InternationalIndia, France strengthen counter-terror ties with NSG-GIGN Letter of Intent in Paris

NationalRJD hits out at NDA for promoting dynastic politics in new Bihar govt formation

HockeyJunior India women's hockey team sharpen defence ahead of World Cup, captain Jyoti confident against Germany

Technology Realted Stories

TechnologyIITF 2025: Artisans, exhibitors hail govt support amid record footfall

TechnologyGovt launches Centre of Logistics Training Excellence in Hyderabad to boost tech‑led logistics skilling

TechnologyGoogle announces anti-scam tools, AI safety efforts for kids, elderly users in India

TechnologyNHAI to launch Raajmarg Infra Investment Managers to drive public InvIT Initiative

TechnologyUNICEF lauds India for ‘significant progress’ in poverty reduction, investments in children